---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-007858"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2022-03-01T23:59:59+00:00"
generated_at: "2026-06-27T03:05:42.444113+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma reports FY2021 net loss of $57.8M; cash at $314.1M; PC14586 data expected H1 2022

## Summary
- Net loss $57.8M in FY2021 vs $34.4M in FY2020; R&D expenses $36.5M; G&A $21.8M.
- Cash, cash equivalents and marketable securities $314.1M as of Dec 31, 2021 vs $361.4M Dec 31, 2020; net cash used in operations $46.6M.
- Lead candidate PC14586 Phase 1/2 trial ongoing; initial Phase 1 data expected in first half of 2022.
- Advanced WIP1 inhibitor program into lead optimization; appointed Kirsten Flowers to Board of Directors.

## SEC filing metadata
- accession: 0001564590-22-007858
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2022-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000156459022007858/0001564590-22-007858-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000156459022007858/pmvp-8k_20220301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-007858
- JSON: https://secwatch.observer/filing/0001564590-22-007858.json
- Plain text: https://secwatch.observer/filing/0001564590-22-007858.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.